| Size | Price | |
|---|---|---|
| 1mg | ||
| Other Sizes |
| Targets |
Reactive Oxygen Species (ROS) signaling pathways. Isorabaichromone acts as a free radical scavenger targeting DPPH radicals and superoxide anions. It neutralizes these reactive species, reducing oxidative stress levels in biological systems. The compound's antioxidant properties are mediated through its ability to donate hydrogen atoms or electrons to stabilize unpaired electrons in free radicals, thereby preventing radical chain reactions that cause cellular damage.
|
|---|---|
| ln Vitro |
Isorabaichromone exhibits potent antioxidative properties in cell-free systems, including DPPH radical and superoxide anion scavenging activities. DPPH assay results demonstrate that the compound effectively reduces the stable free radical DPPH, as evidenced by a decrease in absorbance at 517 nm. Superoxide anion scavenging activity has also been confirmed, indicating broad-spectrum free radical neutralization. The compound shows potent antioxidative activity, comparable to or exceeding other known antioxidant reference compounds.
|
| ln Vivo |
In vivo studies using electron spin resonance (ESR) with spin trapping methods have suggested that the potent superoxide anion scavenging activity of Isorabaichromone may contribute to its antioxidant effects in biological systems. The compound's ability to scavenge superoxide anions in animal models indicates its potential for reducing oxidative stress-related pathologies. Additionally, its structural similarity to other bioactive chromones suggests possible anti-inflammatory and neuroprotective effects in vivo, though more detailed animal studies are needed to fully characterize these activities.
|
| Enzyme Assay |
DPPH radical scavenging assay: Prepare Isorabaichromone test solutions at multiple concentrations (0-100 uM) in appropriate solvent (e.g., methanol or DMSO). In a 96-well plate, add 100 uL of each test concentration and 100 uL of 0.1 mM DPPH methanolic solution. Include blank control (solvent) and positive control (e.g., quercetin). After mixing, incubate the plate in the dark at room temperature for 30 minutes. Measure absorbance at 517 nm using a microplate reader. Calculate % radical scavenging activity and determine IC₅0 values from concentration-response curves. Superoxide scavenging activity can be assessed using a xanthine/xanthine oxidase system combined with NBT reduction assay.
|
| Cell Assay |
Cells are seeded in 96-well plates at appropriate density. After adherence, cells are pre-incubated with varying concentrations of Isorabaichromone (1-100 uM) for 2-4 hours. Oxidative stress is induced by treating with H2O2 (100-500 uM) or other oxidants for 1-4 hours. Cellular ROS levels are measured using DCFH-DA probe (10 uM, 30 minutes) with fluorescence detection at excitation/emission 485/535 nm. Cell viability is assessed via MTT or CCK-8 assay. Lipid peroxidation may be quantified using malondialdehyde (MDA) assay. All samples should be run in triplicate.
|
| Animal Protocol |
Animal models (e.g., mice or rats) are administered Isorabaichromone orally or intraperitoneally at doses ranging from 10-100 mg/kg daily for 1-4 weeks. Blood and tissue samples are collected for analysis of oxidative stress biomarkers (MDA, SOD, GSH, catalase). Inflammatory markers including TNF-alpha, IL-6, and IL-1beta may be quantified by ELISA. For specific disease models, additional endpoints such as organ protection, cognitive function, or inflammation reduction are evaluated. Isorabaichromone's in vivo effects are compared to vehicle-treated controls.
|
| ADME/Pharmacokinetics |
Isorabaichromone has a molecular weight of 572.56 and molecular formula C2₉H32O12. Solubility information: soluble in DMSO and other organic solvents. For in vivo studies, formulations using DMSO:PEG300:Tween 80:Saline (10:40:5:45) are recommended. The compound should be stored as powder at -20degC (stable for 3 years) and in solution at -80degC (stable for 1 year). Detailed pharmacokinetic parameters (half-life, Cmax, AUC, bioavailability) have not been extensively reported in the literature.
|
| Toxicity/Toxicokinetics |
Based on its natural product origin and use in traditional contexts, Isorabaichromone is expected to have low acute toxicity. The compound is an effective antioxidant agent, and no significant adverse effects have been reported in available literature at experimental doses. However, standard acute and chronic toxicological studies have not been extensively performed. As with all research chemicals, appropriate safety precautions should be taken when handling. Further safety evaluation would be needed for potential therapeutic applications.
|
| References | |
| Additional Infomation |
Reports indicate that aloe vera contains isorabacterone, and relevant data is available for reference.
Isorabaichromone is a natural antioxidant that has been studied in the context of traditional medicine and phytochemistry. It exhibits not only DPPH radical scavenging but also superoxide anion scavenging activity, making it a broad-spectrum free radical neutralizer. The compound has been identified in certain plant species known for medicinal properties. It is available for research use only, not for human therapeutic applications. The compound should be stored under appropriate conditions to maintain stability. Store powder at -20degC, protecting from light and moisture. |
| Molecular Formula |
C29H32O12
|
|---|---|
| Molecular Weight |
572.557189941406
|
| Exact Mass |
572.189
|
| CAS # |
194669-79-9
|
| PubChem CID |
10370832
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
1.4
|
| Hydrogen Bond Donor Count |
6
|
| Hydrogen Bond Acceptor Count |
12
|
| Rotatable Bond Count |
9
|
| Heavy Atom Count |
41
|
| Complexity |
983
|
| Defined Atom Stereocenter Count |
6
|
| SMILES |
C1(C[C@@H](O)C)OC2=C([C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3OC(=O)/C=C/C3=CC=C(O)C(O)=C3)C(OC)=CC(C)=C2C(=O)C=1
|
| InChi Key |
DWFAOPWLORYRCM-VLFSRZOJSA-N
|
| InChi Code |
InChI=1S/C29H32O12/c1-13-8-20(38-3)24(27-23(13)19(34)11-16(39-27)9-14(2)31)28-29(26(37)25(36)21(12-30)40-28)41-22(35)7-5-15-4-6-17(32)18(33)10-15/h4-8,10-11,14,21,25-26,28-33,36-37H,9,12H2,1-3H3/b7-5+/t14-,21+,25+,26-,28-,29+/m0/s1
|
| Chemical Name |
[(2S,3R,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-2-[2-[(2S)-2-hydroxypropyl]-7-methoxy-5-methyl-4-oxochromen-8-yl]oxan-3-yl] (E)-3-(3,4-dihydroxyphenyl)prop-2-enoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.7465 mL | 8.7327 mL | 17.4654 mL | |
| 5 mM | 0.3493 mL | 1.7465 mL | 3.4931 mL | |
| 10 mM | 0.1747 mL | 0.8733 mL | 1.7465 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
